Cigna (CI) Stock Still Looks Undervalued On Connected Benefits Launch

Cigna Group stock has delivered a solid gain over the past five years, yet the shares now carry a high value score and screen as undervalued on market multiples. This puts the recent muted returns into sharper focus. With the company rolling out products like its new Connected Benefits offering, investors are weighing whether the current price fairly reflects the longer term potential and risks in the business.

• Cigna Group has returned about 41.0% over the past 5 years, which frames the stock as a steady compounder rather than a recent high flyer.
• The launch of Connected Benefits may support expectations for stronger engagement in Cigna Healthcare products, while ongoing regulatory scrutiny of its pharmacy benefit model can pressure margins and investor sentiment.
• With a high value score of 6, the broader checks lean cheap relative to where the stock trades today.

The issue now is whether Cigna Group's recent share price, after modest short term declines, offers a reasonable entry point for investors who focus on valuation first.

Compare Cigna Group with a curated list of other undervalued opportunities by scanning the 45 high quality undervalued stocks that share a similar focus on fundamentals and pricing gaps.

Is Cigna Group a Bargain on Earnings?

The P/E ratio is a useful way to think about what you are paying today for Cigna Group’s current earnings power. It links directly to the company’s profitability, which is central for a mature healthcare insurer.

Cigna Group trades on a P/E of about 11.5x. This sits well below the broader Healthcare industry average of 25.0x and also below the peer average of 31.6x. The Fair Ratio model, which adjusts for factors such as sector, size and risk profile, points to a P/E of 28.7x as a reasonable reference. That is a wide gap to the current multiple. Despite the launch of Connected Benefits giving Cigna Group a fresh product talking point, the market is still pricing its earnings at a clear discount to sector and peer benchmarks.

On the P/E multiple, Cigna Group stock appears undervalued compared with both its industry and what the Fair Ratio model suggests as a more typical earnings valuation.

See what the numbers say about this price — find out in our valuation breakdown.

The Cigna Group Narrative: What Would Justify Today's Price?

Narratives pick up where the Cigna Group valuation puzzle leaves off by explaining which paths for growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. They appear on Simply Wall St’s Community page. Each one turns Cigna Group's implied fair value into a thesis about the business that you can track over time rather than a single point in time.

Share a Narrative on Cigna Group in the Simply Wall St community to set out a number driven case that other investors can track as new results and products like Connected Benefits play through the business.

Use the recent launch of Cigna Healthcare’s Connected Benefits as a chance to add your voice on whether the current valuation makes sense given Cigna Group's earnings profile and product line up.

Do you think there's more to the story for Cigna Group? Head over to our Community to see what others are saying!

The Bottom Line

Cigna Group screens as undervalued on earnings multiples, with the current P/E sitting well below both industry and peer benchmarks. The high value score suggests those broader checks are aligned with that signal rather than pushing back on it. For you as an investor, the real question is whether the discount reflects mispricing or an appropriate cushion for regulatory and execution risks around offerings like Connected Benefits. The crux of the debate is whether Cigna Group can sustain its earnings profile in a way that eventually narrows the valuation gap without eroding margins.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com